These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31031206)

  • 41. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
    O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
    Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
    Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
    World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis.
    Durczynski A; Kumor A; Grzelak P; Strzelczyk M; Hogendorf P; Poznanska G; Skulimowski A; Szymanski D; Strzelczyk J
    Pancreas; 2017 Jan; 46(1):e9-e10. PubMed ID: 27763956
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
    Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages.
    Matsumoto S; Harada H; Tanaka J; Ochi K; Seno T; Tsurumi T; Kunichika K
    Pancreas; 1994 Nov; 9(6):741-7. PubMed ID: 7846018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.
    Yasue M; Sakamoto J; Teramukai S; Morimoto T; Yasui K; Kuno N; Kurimoto K; Ohashi Y
    Pancreas; 1994 Nov; 9(6):735-40. PubMed ID: 7846017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1.
    Attallah AM; El-Far M; Ibrahim AR; El-Desouky MA; Omran MM; Elbendary MS; Attallah KA; Qura ER; Abdallah SO
    Br J Biomed Sci; 2018 Jul; 75(3):122-127. PubMed ID: 29734875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A comparative study on serum immunoglobulin and tumor marker levels in the patients with autoimmune pancreatitis and pancreatobiliary malignancies].
    Yoon H; Kim MH; Won SH; Park DH; Lee SS; Seo DW; Lee SK
    Korean J Gastroenterol; 2013 Jun; 61(6):327-32. PubMed ID: 23877213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ERCP combined with tumor markers in differential diagnosis of pancreatic cancer and pseudotumor-like pancreatitis.
    Luo B; Peng F; Hong M; Su S; Fang C; Yang X; Xia G; Li B
    J BUON; 2019; 24(4):1568-1573. PubMed ID: 31646810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
    Su SB; Qin SY; Chen W; Luo W; Jiang HX
    World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
    Satake K; Takeuchi T
    Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.
    Ueda M; Kamada Y; Takamatsu S; Shimomura M; Maekawa T; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kobayashi Y; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    Pancreatology; 2016; 16(2):238-43. PubMed ID: 26897254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
    Changchine CS; Yung CY; Tzen KY
    Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.